{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:09:37Z","timestamp":1772755777052,"version":"3.50.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.revmed.2015.10.348","type":"journal-article","created":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T09:16:13Z","timestamp":1457514973000},"page":"564-566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Syndrome d\u2019activation macrophagique sous tocilizumab\u00a0: mythe ou r\u00e9alit\u00e9\u00a0?"],"prefix":"10.1016","volume":"37","author":[{"given":"A.","family":"Deroux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Andry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Bouillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2015.10.348_bib0070","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1586\/eci.10.70","article-title":"Tocilizumab for the treatment of rheumatoid arthritis","volume":"6","author":"Tanaka","year":"2010","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.revmed.2015.10.348_bib0075","series-title":"Assessment report for RoActemra. International nonproprietary name: tocilizumab","author":"European Medicines Agency (EMEA)","year":"2011"},{"key":"10.1016\/j.revmed.2015.10.348_bib0080","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2015.10.348_bib0085","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1546-0096-10-30","article-title":"Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome","volume":"10","author":"Kessler","year":"2012","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.revmed.2015.10.348_bib0090","series-title":"Assessment report for RoActemra. EMEA\/H\/C\/955\/X\/0030","author":"European Medicines Agency","year":"2014"},{"key":"10.1016\/j.revmed.2015.10.348_bib0095","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2015.10.348_bib0100","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004. Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.revmed.2015.10.348_bib0105","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.cyto.2012.02.006","article-title":"Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6","volume":"58","author":"Shimizu","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.revmed.2015.10.348_bib0110","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2015.10.348_bib0115","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3899\/jrheum.140288","article-title":"Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab","volume":"42","author":"Yokota","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2015.10.348_bib0120","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/rheumatology\/keu019","article-title":"Fulminant myocarditis and macrophage activation syndrome secondary to adult-onset Still's disease successfully treated with tocilizumab","volume":"53","author":"Savage","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2015.10.348_bib0125","first-page":"1","article-title":"Short-term add-on tocilizumab and intravenous cyclophosphamide exhibited a remission-inducing effect in a patient with systemic lupus erythematosus with refractory multiorgan involvements including massive pericarditis and glomerulonephritis","volume":"30","author":"Iwai","year":"2014","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.revmed.2015.10.348_bib0065","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.clinthera.2012.02.014","article-title":"Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor","volume":"34","author":"Navarro-Mill\u00e1n","year":"2012","journal-title":"Clin Ther"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866315010413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866315010413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:36:58Z","timestamp":1759336618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866315010413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0248866315010413"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2015.10.348","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Syndrome d\u2019activation macrophagique sous tocilizumab\u00a0: mythe ou r\u00e9alit\u00e9\u00a0?","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2015.10.348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}